Process Development and GMP Production of a Conjugate Warhead: Auristatin F-HPA-Ala/TFA (XMT-1864/TFA)-Reference-Cited by-同舟云学术

Process Development and GMP Production of a Conjugate Warhead: Auristatin F-HPA-Ala/TFA (XMT-1864/TFA)

Published:2022-02-15 Issue:8 Volume:26 Page:2124-2137
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Conlon Patrick R.¹,Gurijala Venu Reddy²,Kaufman Michael¹,Li Dachang³,Li Jiuyuan³,Li Yuanyuan²,Yin Mao¹,Reddy Bollu Satyanarayan²,Wagler Thomas²,Wang Zedong³,Xu Zhongmin⁴,Yurkovetskiy Aleksandr V.¹,Zhu Lei²^ORCID

Affiliation:

1. Former Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts 02139, United States

2. Drug Substance Development, Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts 02139, United States

3. Chemical Macromolecule Division, Asymchem Life Science (Tianjin) Co., Ltd. No. 71, Seventh Avenue, TEDA Tianjin 300457, P.R. China

4. Chemdiscover, 10 Carlton Circle, Princeton, New Jersey 08540, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.1c00449

Reference30 articles.

1. Antibody-drug conjugates (ADCs): Potent biopharmaceuticals to target solid and hematological cancers- an overview

2. Antibody–drug conjugates for cancer

3. Antibody-drug conjugates: an emerging modality for the treatment of cancer

4. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer

5. New developments for antibody-drug conjugate-based therapeutic approaches

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios;Molecular Cancer Therapeutics;2023-09-29

2. Drug-Linkers in Antibody–Drug Conjugates: Perspective on Current Industry Practices;Organic Process Research & Development;2023-06-29